Paul H. Edelstein, MD
Edelstein P.; Antimicrobial Chemotherapy for Legionnaires Disease: Time for a Change. Ann Intern Med. 1998;129:328-330. doi: 10.7326/0003-4819-129-4-199808150-00012
Download citation file:
Published: Ann Intern Med. 1998;129(4):328-330.
Erythromycin became the de facto standard of treatment for Legionnaires disease soon after the first recognized epidemic of this disease occurred 22 years ago [1, 2]. However, it is now time for a change in therapy because of increasing evidence of the superiority of newer antimicrobial agents. The conclusion that erythromycin is the drug of choice for Legionnaires disease was based on unavoidably imperfect retrospective analysis of treatment outcomes from the epidemic, which showed the lowest overall fatality rates with either erythromycin or tetracycline therapy. No prospective comparative studies with adequate statistical power of the treatment of Legionnaires disease have been published. Because of the relative rarity of Legionnaires disease and its widely varying outcomes, it is unlikely that an adequate comparative clinical trial of the disease will ever be completed; such a study would need to have 300 to 900 patients with the disease in each experimental group to have adequate statistical power . This means that decisions about new therapy must be based on laboratory experiments and limited clinical data.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, Pulmonary/Critical Care.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only